» Articles » PMID: 21511353

Tendering for Outpatient Prescription Pharmaceuticals: What Can Be Learned from Current Practices in Europe?

Overview
Journal Health Policy
Date 2011 Apr 23
PMID 21511353
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To explore the current status (2010) of tendering programs for outpatient pharmaceuticals in the European countries and how these programs operate.

Methods: A survey was designed to assess the features of tendering programs in European countries. All 27 countries of the European Union plus Norway were included in the study. The survey was sent to national representatives of authorities and organizations and to academic researchers with expertise in the domain.

Results: Nineteen of the 28 countries have responded to the questionnaire (68%). Seven countries have adopted tendering programs for pharmaceuticals in ambulatory care. Tendering was more popular in countries with a mature generic medicines market (54%) than in countries with a developing generic medicines market (12.5%). A legal basis, criteria to grant the tender, the number of winners and the duration of the tender were amongst the features for the program to work.

Conclusions: Tendering programs can achieve savings in the short term. There are however some problems allied with the policy and the effects in the long term are still unclear. It can be concluded that the policy can work, but the features of the programs have to be well-thought-out.

Citing Articles

The impact of the centralized volume-based procurement policy on Chinese pharmaceutical manufacturing firms' R&D investment: A difference-in-differences approach.

Qiu F, Chen S, Li Y, Wang X, Zhu M PLoS One. 2025; 20(1):e0315811.

PMID: 39752452 PMC: 11698415. DOI: 10.1371/journal.pone.0315811.


The impact of EU public procurement regulations on tenders in Spain: a study with adalimumab.

Esplugues F, Andujar I, Esplugues J Front Pharmacol. 2024; 15:1447324.

PMID: 39364047 PMC: 11446848. DOI: 10.3389/fphar.2024.1447324.


The cost of total hip arthroplasty: compare the hospitalization costs of national centralized procurement and national volume-based procurement.

Fan Y, Xu Q, Jin G, Jiang L, Wang C Front Public Health. 2024; 12:1383308.

PMID: 39040867 PMC: 11260701. DOI: 10.3389/fpubh.2024.1383308.


Impact of National Centralized Drug Procurement policy on chemical pharmaceutical enterprises' R&D investment: a difference-in-differences analysis in China.

Li J, Zhang X, Wang R, Cao K, Wan L, Ren X Front Public Health. 2024; 12:1402581.

PMID: 39011324 PMC: 11247172. DOI: 10.3389/fpubh.2024.1402581.


The vacated space of volume/price of the drugs centralized procurement with quantity in secondary and above public hospitals of China.

Wang J, Zhang S, Wang C, Li J, Wang R, Zhu L BMC Health Serv Res. 2024; 24(1):771.

PMID: 38951849 PMC: 11218069. DOI: 10.1186/s12913-024-11217-3.